Cambridge Laboratories, Helsinn Healthcare SA deal

Cambridge licensed exclusive marketing rights in the U.K. to Helsinn's palonosetron 5-HT3 receptor antagonist to prevent nausea and vomiting induced by chemotherapy. The compound is marketed in the U....